To this effect, we have applied a proteomics study to identify potential biomarkers by comparing BRCA1-mutated immortalized ovarian surface epithelial (OSE) cells, genetically predisposed to ovarian cancer due to the expression of a mutated BRCA1, to wild-type immortalized OSE cells, since women with a germ-line mutation in the BRCA1 gene have a cumulative lifetime risk of 40–50% for ovarian cancer (9). Here, BRCA1 is linked to ovarian carcinoma.